TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
- InSilico seeks IPO boost to get AI drugs over the line
